pain-management-2018-posters-abstracts

23 / 25

Page 98
conferenceseries.com
Volume 7 Journal of Pain & Relief
ISSN: 2167-0846 Pain Management 2018
October 11-12, 2018
October 11-12, 2018 | Zurich, Switzerland
7th International Conference and Exhibition on
Pain Research and Management
Clinical applications of electronic signal treatment and the combined electrochemical treatment
Robert H Odell
Neuropathy and Pain Centers of America, USA
The combined electrochemical treatment (CET) uses local anesthetics combined with advanced electronic cell signaling
technology (EST) to mitigate or eliminate pain, allodynia, numbness and other symptoms of neuropathic pain. Its
physiological actions are better understood using the principles of physics rather than pharmacology. In 2012, Brill noted
that pharmaceuticals, which met Class I evidence-based standards for treating PPN, did not help the majority of PPN patients
who received them, had significant adverse side effects and that interventions aimed at nerve regeneration may need to be
employed. In 2015, Finnerup performed a systematic review and meta-analysis of the data describing pharmacotherapy for
neuropathic pain, concluding that inadequate response to drug treatments constitutes a substantial unmet need in patients
with neuropathic pain. In 2016, Rosenquist presented a systematic review and meta-analysis of available data concerning the
pharmacologic treatment for peripheral neuropathy and concluded that it was marginal, frustrating and maybe even appalling.
CET has been used to treat many forms of peripheral neuropathy, using ankle nerve blocks with EST. We have treated hundreds
of peripheral neuropathic patients with an 80%+ success rate. Epidermal nerve fiber density testing shows nerve regeneration is
occurring. Patients with peripheral neuropathies have shown significant symptom reduction and motor function improvement
(especially foot drop). Patients experience reductions of pain, paresthesias, dysesthesias, allodynia and numbness, increase
in strength and balance and improved quality of life. Long-term benefits include decreased medication use, improvement
of balance, sleep and function occurs in a plurality of patients. An early retrospective study showed that 51% of patients
maintained their improvements. Our overall clinical experience is now closer to 70%. Long term benefits to society include a
significant preservation of healthcare resources since there are virtually no side effects and no recurring drug expenses with
the CET approach.
J Pain Relief 2018, Volume 7
DOI: 10.4172/2167-0846-C1-021